Browne L Daniel Form 4 March 19, 2019

FORM 4

OMB APPROVAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SECURITIES

OMB 3235-0287 Number:

Check this box if no longer subject to Section 16. Form 4 or Form 5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

January 31, Expires: 2005 Estimated average

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations

burden hours per response... 0.5

may continue. See Instruction

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(City)

1.Title of

Security

(Print or Type Responses)

1. Name and Address of Reporting Person * Browne L Daniel			2. Issuer Name and Ticker or Trading Symbol Revance Therapeutics, Inc. [RVNC]	5. Relationship of Reporting Person(s) to Issuer			
(Last) C/O REVAN INC., 7555 G BOULEVAR	ATEWAY	(Middle) PEUTICS,	3. Date of Earliest Transaction (Month/Day/Year) 03/15/2019	(Check all applicable) _X_ Director 10% Owner _X_ Officer (give title Other (specify below) CEO and President			
NEWARK, C	(Street) CA 94560		4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			

(State)	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
2. Transaction Date	2A. Deemed	3.	4. Securities Acquired (A)	5. Amount of	6.	7. Nature of			
(Month/Day/Year)	Execution Date, if	Transactio	or Disposed of (D)	Securities	Ownership	Indirect			
	any	Code	(Instr. 3, 4 and 5)	Beneficially	Form:	Beneficial			
	(Month/Day/Year) (Instr. 8)			Owned	Direct (D)	Ownership			
				Following	or Indirect	(Instr. 4)			
			(4)	Reported	(I)				
			(A)	Transaction(s)	(Instr. 4)				
			or	(Instr. 3 and 4)					

(Instr. 3)		any (Month/Day/Year)	Code (Instr. 8)	(Instr. 3, 4	(A) or	ĺ	Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Form: Direct or Ind (I) (Instr.
Common Stock	03/15/2019		Code V F	Amount 3,256 (1)	(D)	Price \$ 15.45	165,687	D
Common Stock	03/15/2019		F	2,881 (2)	D	\$ 15.45	162,806	D
Common Stock	03/18/2019		S(3)	11,613	D	\$ 15.5057 (4)	151,193	D

See Common 409 I footnote Stock (5)

Edgar Filing: Browne L Daniel - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

 Title of 	2.	3. Transaction Date	3A. Deemed	4.		5.	6. Date Exerc	cisable and	7. Tit	le and	8. Price of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transa	ction	Number	Expiration D	ate	Amou	ınt of	Derivative
Security	or Exercise		any	Code		of	(Month/Day/	Year)	Unde	rlying	Security
(Instr. 3)	Price of		(Month/Day/Year)	(Instr.	8)	Derivative	•		Secur	ities	(Instr. 5)
	Derivative		•			Securities			(Instr	. 3 and 4)	
	Security					Acquired			Ì		
	Ĭ					(A) or					
						Disposed					
						of (D)					
						(Instr. 3,					
						4, and 5)					
						, ,					
										Amount	
							Date	Expiration		or	
						Exercisable	Date	Title	Number		
							LACICISAUIC	Date		of	
				Code	V	(A) (D)				Shares	

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Browne L Daniel C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BOULEVARD NEWARK, CA 94560

X

CEO and President

Signatures

/s/ Gordon Ho, Attorney-in-Fact 03/19/2019

**Signature of Reporting Person Dat

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents the number of shares withheld by and surrendered to the issuer on March 15, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock Award ("RSA") for 28,250 shares. The RSA vests in three equal annual installments from March 15, 2018, subject to Mr. Browne's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
- Represents the number of shares withheld by and surrendered to the issuer on March 15, 2019, to satisfy tax withholding obligations that

 (2) arose in connection with the vesting of an RSA for 25,000 shares. The RSA vests in three equal annual installments from March 15, 2016, subject to Mr. Browne's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.

Reporting Owners 2

9. Nu Deriv Secur Bene Own Follo Repo Trans

SEC 1474

(9-02)

Edgar Filing: Browne L Daniel - Form 4

- (3) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Browne.
- The price reported in Table 1, Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$15.19 to \$15.74. Mr. Browne undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the
- ranging from \$15.19 to \$15.74. Mr. Browne undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- (5) These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust. Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.